Appili Therapeutics Inc (APLI) - Total Liabilities

Latest as of December 2025: CA$16.93 Million CAD ≈ $12.25 Million USD

Based on the latest financial reports, Appili Therapeutics Inc (APLI) has total liabilities worth CA$16.93 Million CAD (≈ $12.25 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Appili Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.

Appili Therapeutics Inc - Total Liabilities Trend (2017–2025)

This chart illustrates how Appili Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See APLI free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Appili Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Appili Therapeutics Inc ranked by their total liabilities.

Company Country Total Liabilities
Macfarlane Group PLC
LSE:MACF
UK GBX157.23 Million
Vault Strategic Mining Corp.
V:KNOX
Canada CA$859.97K
Ucommune International Ltd
NASDAQ:UK
USA $74.20 Million
Rajdarshan Industries Limited
NSE:ARENTERP
India Rs3.15 Million
Univa Foods Limited
NSE:UNIVAFOODS
India Rs10.79 Million
Uniinfo Telecom Services Limited
NSE:UNIINFO
India Rs99.34 Million
Mercia Technologies PLC
LSE:MERC
UK GBX15.58 Million
Valora Effekten Handel AG
F:VEH
Germany €608.96K

Liability Composition Analysis (2017–2025)

This chart breaks down Appili Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Appili Therapeutics Inc (APLI) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.03 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 30.90 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Appili Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Appili Therapeutics Inc (2017–2025)

The table below shows the annual total liabilities of Appili Therapeutics Inc from 2017 to 2025.

Year Total Liabilities Change
2025-03-31 CA$16.43 Million
≈ $11.89 Million
+32.34%
2024-03-31 CA$12.42 Million
≈ $8.98 Million
+17.91%
2023-03-31 CA$10.53 Million
≈ $7.62 Million
-8.85%
2022-03-31 CA$11.55 Million
≈ $8.36 Million
+107.62%
2021-03-31 CA$5.56 Million
≈ $4.02 Million
+138.96%
2020-03-31 CA$2.33 Million
≈ $1.68 Million
-3.59%
2019-03-31 CA$2.42 Million
≈ $1.75 Million
+3.95%
2018-03-31 CA$2.32 Million
≈ $1.68 Million
+94.78%
2017-03-31 CA$1.19 Million
≈ $862.92K
--

About Appili Therapeutics Inc

TO:APLI Canada Biotechnology
Market Cap
$1.39 Million
CA$1.93 Million CAD
Market Cap Rank
#30333 Global
#1544 in Canada
Share Price
CA$0.02
Change (1 day)
+50.00%
52-Week Range
CA$0.01 - CA$0.04
All Time High
CA$1.87
About

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more